GO
Loading...

Enter multiple symbols separated by commas

Medicine

More

  • Biotech Bonanza For ImClone & Dendreon Monday, 6 Oct 2008 | 10:56 AM ET
    imclone_logo_new.jpg

    Okay, what were the chances that ImClone would get bought and Dendreon would come out with its interim test results on the same morning? Slim to none, I'd say. But that's exactly what the news gods had in store for two of the hottest names in biotech.

  • Dendreon, ImClone & Pfizer: Your Emails Friday, 3 Oct 2008 | 10:37 AM ET

    As all eyes remain on Capitol Hill, things remain relatively quiet on the biopharma front. So, it's a good time to go through the Pharma's Market mailbag. The overwhelming majority of emails recently have been about...yeah, you guessed it...Dendreon.

  • While the Street is focused on the big vote in the Senate tonight on the bailout package, biotech investors will be on the lookout for news out of ImClone Systems. Earlier this week the company announced that its mystery counter-bidder will decide whether to follow through on its $70-a-share offer by midnight tonight.

  • The Waiting Game Continues For Lilly & ImClone Monday, 29 Sep 2008 | 10:42 AM ET
    lilly_hq.jpg

    Eli Lilly has been running direct-to-doctor ads over the past few months telling physicians that Effient, the company's new bloodthinner, is "Coming Soon". Well, it may have jumped the gun.

  • Lilly

    Today is the day the FDA is expected to make a decision on the drug. The agency could approve it outright, approve it with conditions/limitations, delay making a decision--again--and order more tests, or reject the pill.

  • Mardi Gras Beads

    There are reports of booze, women and beads--as in Mardi Gras beads. Specifically, the piece cites allegations from a lawsuit brought by a former MDT attorney who says the medical device maker sponsored a "discussion group" outing to New Orleans.

  • merck_manual.jpg

    As the press release that came with the book says, "Compact enough to carry in a lab coat pocket, the paperback helps health care practitioners, particularly those who are newcomers to clinical diagnosis, understand and evaluate a wide range of symptoms."

  • Pfizer Is A Driver: "Complaining" Investor Read On! Thursday, 18 Sep 2008 | 4:40 PM ET
    pfizer_hq.jpg

    The stock posted its biggest percentage gain in nearly three years and its biggest dollar gain in more than two years, according to CNBC stock-stat maven Robert Hum.

  • Lilly Loves Lechleiter--But Stock Moves On Other "News" Thursday, 18 Sep 2008 | 11:33 AM ET
    lilly_hq.jpg

    New Eli Lilly CEO John Lechleiter today joins the list of the recent fresh crop of big pharma honchos who've been elevated to Chairman of the Board as well. But that's not what's moving shares of LLY higher this morning.

  • Abbott & Boston Scientific: Rising Stent Stars Wednesday, 17 Sep 2008 | 12:21 PM ET
    Boston Scientific Corp.

    Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging.

  • Putting My Finger On The BlackBerry Addiction Friday, 12 Sep 2008 | 2:03 PM ET
    splint.jpg

    Yesterday afternoon I became a statistic. I am now among the reportedly growing number of people getting injured while texting and--not driving--but walking.

  • ImClone-Bristol Battle Is Really Gettin' Good Friday, 12 Sep 2008 | 9:57 AM ET
    imclone_logo_new.jpg

    I finished my last ImClone Systems vs. Bristol-Myers Squibb entry asking what Bristol had to say about IMCL's claim of a mystery outbidder. Well, yesterday we found out in a press release from BMY.

  • Pfizer: A Delay And A Deal? Tuesday, 9 Sep 2008 | 12:06 PM ET

    At the risk of getting more emails from conspiracy-theorist readers who think I report too much negative news about Pfizer, here comes another setback for the world's biggest drug company.

  • Pharma Stocks

    John Sullivan, the Director of Research at Lerrink Swann, which specializes in healthcare stocks, says there is a potential trading opportunity in the sector related to F & F.

  • Lilly's Brewing Battle With Bristol And Your Emails Friday, 5 Sep 2008 | 12:58 PM ET
    Effient Ad

    Earlier this week I blogged about Eli Lilly's "Coming Soon" banner ad I spotted in the online edition of "The New England Journal of Medicine." It's designed to generate buzz about the company's crucial new bloodthinner that could win Food and Drug Administration approval this month.

  • At The End Of The Day: Dendreon Thursday, 4 Sep 2008 | 4:30 PM ET
    dendreon_logo_new2.jpg

    Dendreonians, the wait is over. Dendreon had the second-to-last time slot at the BioCentury/Thomson Reuters biotech investment conference this afternoon.

  • Orexigen And Its Obesity Bets Thursday, 4 Sep 2008 | 11:51 AM ET
    Orexigen

    After Medivation, I moved onto the Orexigen presentation. It's a company I profiled at when it had data on one of its fat-fighting drugs at last year's diabetes conference, so I wanted to check up on its progress.

  • Medivation's Presentation Thursday, 4 Sep 2008 | 10:18 AM ET
    Medivation

    A little more than 24 hours after announcing its big, lucrative Alzheimer's drug partnership with Pfizer, Medivation had the lead-off position (I wonder if they told organizers they'd be a newsmaker) at today's BioCentury/Thomson Reuters biotech investment conference in New York City.

  • Biotech Bonanza At Industry Conference Thursday, 4 Sep 2008 | 9:09 AM ET

    Today I will be attending and blogging from the 15th Annual Newsmakers in the Biotech Industry conference which is put on by BioCentury Publications and Thomson Reuters. Three dozen biotechs will be making presentations and then doing hour-long q and a's during breakout sessions.

  • Pfizer Finding Innovation At Medivation Wednesday, 3 Sep 2008 | 10:32 AM ET
    Lilly Effient

    In late July at a big scientific conference in Chicago, I reported on new, positive data on Medivation's experimental Alzheimer's drug Dimebon (dim-uh-bahn).